Activity of Daflon 500 mg on the hemorheological disorders in diabetes.
A rheological study was performed on blood samples from 10 insulin-treated diabetics with retinopathy. As part of their treatment, they all received 4 tablets of Daflon 500 mg per day for 30 days. Three complementary rheological criteria were used to characterize blood samples: 1) viscometry, using a Couette viscometer, which produces data on viscosity, shear-thinning, viscoelasticity and tixotropy of blood, 2) aggregametry, using an apparatus based on light reflectometry, using a filtrometer based on the deformations red cells undergo as they pass through narrow pores which produces information on red cell deformability. The main results were: a better red blood cell disaggregability, a decrease in red blood cell aggregation and no change in red blood cell deformability.
Lacombe
C
C
Unité de Biorhéologie, CHU Pitié-Salpêtrière, France.
Lelievre
J C
JC
Bucherer
C
C
Grimaldi
A
A
D000328:Adult; D000368:Aged; D001809:Blood Viscosity / Q000187:drug effects; D003930:Diabetic Retinopathy / Q000097:blood*; D004145:Diosmin / Q000494:pharmacology*; D004903:Erythrocyte Aggregation / Q000187:drug effects*; D004907:Erythrocyte Deformability / Q000187:drug effects*; D005340:Fibrinogen / Q000378:metabolism; D005419:Flavonoids / Q000494:pharmacology*; D006801:Humans; D008875:Middle Aged; D012212:Rheology
D005419:Flavonoids; D004145:Diosmin; D005340:Fibrinogen